ArticleInfection and immunity2009
High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay.
Article in Infection and immunity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Protection Elicited by Glutamine Auxotroph ofVaccines · 2025Article
- A novel sORF gene mutant strain of Yersinia pestis vaccine EV76 offers enhanced safety and improved protection against plague.PLoS pathogens · 2024Article
- Protection Elicited by Attenuated LiveVaccines · 2021Article
- Review
- Article
- Plague Vaccines: Status and Future.Advances in experimental medicine and biology · 2016Review
- Production, secretion and purification of a correctly folded staphylococcal antigen in Lactococcus lactis.Microbial cell factories · 2015Article
- Protecting against plague: towards a next-generation vaccine.Clinical and experimental immunology · 2013Review
- Rational considerations about development of live attenuated Yersinia pestis vaccines.Current pharmaceutical biotechnology · 2013Review
- Plague vaccines: current developments and future perspectives.Emerging microbes & infections · 2012Review
- Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients.Clinical and vaccine immunology : CVI · 2012Article
- Immunization of mice with recombinant protein CobB or AsnC confers protection against Brucella abortus infection.PloS one · 2012Article
- Insight into bacterial virulence mechanisms against host immune response via the Yersinia pestis-human protein-protein interaction network.Infection and immunity · 2011Article
- Expression during host infection and localization of Yersinia pestis autotransporter proteins.Journal of bacteriology · 2011Article
- Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Article
- Identification of Brucella abortus virulence proteins that modulate the host immune response.BioengineeredArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yersinia pestis, the plague pathogen, is a facultative intracellular bacterium. Cellular immunity plays important roles in defense against infections. The identification of T-cell targets is critical for the development of effective vaccines against intracellular bacteria; however, the function of cellular immunity in protection from plague was not clearly understood. In this study, 261 genes from Y. pestis were selected on the basis of bioinformatics analysis and previous research results for expression in Escherichia coli BL21(DE3). After purification, 101 proteins were qualified for examination of their abilities to induce the production of gamma interferon in mice immunized with live vaccine EV76 by enzyme-linked immunospot assay. Thirty-four proteins were found to stimulate strong T-cell responses. The protective efficiencies for 24 of them were preliminarily evaluated using a mouse plague model. In addition to LcrV, nine proteins (YPO0606, YPO1914, YPO0612, YPO3119, YPO3047, YPO1377, YPCD1.05c, YPO0420, and YPO3720) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis, but only YPO0606 could partially protect mice from infection with Y. pestis at a higher challenge dosage (200x LD(50)). These proteins would be the potential components for Y. pestis vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.